Johnson & Johnson vs. Danaher: Which Healthcare Stock Looks Better Positioned Following Earnings?
Reported by Yahoo Finance · finance.yahoo.com · July 31, 2026
Johnson & Johnson (NYSE:JNJ) delivered strong fiscal Q2 2026 results, with sales for the quarter growing nearly 7% to $25.31 billion, above analysts’ average estimate of about $25.05 billion. Adjusted earnings per share reached $2.90, surpassing the expectation of $2.85. The company also raised its guidance and stated that it is on track to meet […]
What the tape says
What to watch: Johnson & Johnson (JNJ, DHR) raised guidance toward 7% — confirm the raise reflects durable demand, not a one-time item.
Market reaction today: $JNJ +1.04%, $DHR -1.71%
Tone and severity are deterministic keyword classification — not a prediction, a member vote, or a recommendation. Figures are extracted from the headline as published. Wook does not republish Yahoo Finance's reporting.
Your read
Discussion
No one has weighed in yet. Start the discussion on this story.
Headline and link are attributed to Yahoo Finance. Wook of Wall Street is an independent research tool and is not affiliated with Yahoo Finance. Nothing here is financial advice or a recommendation — research and educational content only.